'Fire and forget?' - Pharmacological considerations in coronary care

Atherosclerosis

Volumn 147, Issue SUPPL. 1, 1999, Pages

  Bottorff, Michael ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Cytochrome P450; Drug interactions; Secondary CHD prevention; Statins

Indexed keywords

ALFENTANIL; AMIODARONE; AMITRIPTYLINE; ASTEMIZOLE; ATORVASTATIN; CARBAMAZEPINE; CERIVASTATIN; CISAPRIDE; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; DICLOFENAC; DILTIAZEM; ERYTHROMYCIN; ETHINYLESTRADIOL; FLUINDOSTATIN; FLUOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MIBEFRADIL; NIFEDIPINE; PHENYTOIN; PRAVASTATIN; QUINIDINE; RITONAVIR; SAQUINAVIR; SIMVASTATIN; STATINE DERIVATIVE; TACROLIMUS; VERAPAMIL; WARFARIN;

ACUTE HEART FAILURE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CHOICE; DRUG EXCRETION; DRUG INTERACTION; DRUG METABOLISM; DRUG SOLUBILITY; FRUIT JUICE; HUMAN; HYDROPHILICITY; HYPERCHOLESTEROLEMIA; INTESTINE; ISCHEMIC HEART DISEASE; LIPOPHILICITY; LIVER; MYOPATHY; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK; SECONDARY PREVENTION; UNSTABLE ANGINA PECTORIS;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR AGENTS; CORONARY DISEASE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 0032880295     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00252-X     Document Type: Conference Paper

References (52)

1. Leor J., Goldbourt U., Reicher-Reiss H. et al. Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: Incidence, risk factors, and outcome. SPRINT study group. Am. J. Med. 94:1993;265-273.
2. Chua T.S., Koo C.C., Tan A.T., Ho C.K. Mortality trends in the coronary care unit. Ann. Acad. Med. Singapore. 19:1990;3-8.
3. Wood D., De Backer G., Faergeman O. et al. On behalf of the Second Joint Task Force of European and other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice. Eur. Heart J. 19:1998;1434-1503.
4. EUROASPIRE Study Group. A European Society of Cardiology survey on secondary prevention of coronary heart disease: principal results. Eur Heart J 1997;18:1569-82.
5. Shepherd J., Cobbe S.M., Ford I. et al. For the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N. Engl. J. Med. 333:1995;1301-1307.
6. Downs J.R., Clearfield M., Weis S. et al. For the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. J. Am. Med. Assoc. 279:1998;1615-1622.
7. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Eng J Med 1998;339:1349-57.
8. Sacks F.M., Pfeffer M.A., Moyle L.A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Eng. J. Med. 335:1996;1001-1009.
9. Scandinavian Simvastatin Survival Study (4S) Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;344:1383-9.
10. Shimada T., Yamazaki H., Mimura M. et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and Caucasians. J. Pharmacol. Exp. Ther. 270:1994;414-423.
11. Kolars J.C., Schmiedlin-Ren P., Dobbins W.O. III et al. Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology. 102:1992;1186-1198.
12. Kivisto K.T., Bookjans G., Fromm M.F. et al. Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br. J. Clin. Pharmacol. 42:1996;387-389.
13. Benet L.Z., Kroetz D.L., Sheiner L.B. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. Hardman J.G., Limbird L.E., Molinoff P.B. et al. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. 1996;3-29 McGraw-Hill, New York.
14. Duggan D.E., Chen I.W., Bayne W.F. et al. The physiological disposition of lovastatin. Drug Metab. Dispos. 17:1989;166-173.
15. Vickers S., Duncan C.A., Chen I.W. et al. Metabolic disposition studies on simvastatin, a cholesterol lowering prodrug. Drug Metab. Dispos. 18:1990;138-145.
16. Wang R.W., Kari P.H., Lu A.Y. et al. Biotransformation of lovastatin IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch. Biochem. Biophys. 290:1991;355-361.
17. Vickers S., Duncan C.A., Vyas K.P. et al. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab. Dispos. 18:1990;476-483.
18. Lea A.P., McTavish D. Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs. 53:1997;828-847.
19. Boberg M., Angerbauer R., Fey P. et al. Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isoenzymes involved. Drug Metab. Dispos. 25:1997;321-331.
20. Fischer V., Johnason L., Heitz F. et al. The 3-hydroxy-3-methylglutaryl coenzyme. A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab. Dispos. 27:1999;410-416.
21. Pan H.Y., DeVault A.R., Wang-Iverson D. et al. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J. Clin. Pharmacol. 30:1990;1128-1135.
22. Horsmans Y., Desager J.P., van den Berge V. et al. Effects of simvastatin and pravastatin on 6-beta-hydroxycortisol excretion, a potential marker of cytochrome P-450 3A. Pharmacol. Res. 28(3):1993;243-248.
23. Singhvi S.M., Pan H.Y., Morrison R.A., Willard D.A. Disposition of pravastatin sodium, a tissue selective HMG-CoA reductase inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 29:1990;239-243.
24. Quion J.A., Jones P.H. Clinical pharmacokinetics of pravastatin. Clin. Pharmacokinet. 27(2):1994;94-103.
25. Azie N.E., Brater D.C., Becker P.A. et al. The interaction of diltiazem with lovastatin and pravastatin. Clin. Pharmacol. Ther. 64(4):1998;369-377.
26. Kantola T., Kivisto K.T., Neuvonen P.J., Kantola T. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin. Pharmacol. Ther. 64:1998;58-65.
27. Neuvonen P.J., Kantola T., Kivisto K.T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther. 63(3):1998;332-341.
28. Kivisto K.T., Kantola T., Neuvonen P.J. Different effects of itraconazole pharmacokinetics of fluvastatin and lovastatin. Br. J. Clin. Pharmacol. 46:1998;49-53.
29. Ducharme M.P., Warbasse L.H., Edwards D.J. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin. Pharmacol. Ther. 57:1995;485-491.
30. Bailey D.G., Arnold J.M.O., Bend J.R. et al. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulations. Br. J. Clin. Pharmacol. 40:1995;135-140.
31. Kupferschmidt H.H.T., Ha H.R., Ziegler W.H. et al. Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther. 58:1995;20-28.
32. Kupferschmidt H.H., Fattinger K.E., Ha H.R. et al. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br. J. Clin. Pharmacol. 45:1998;355-359.
33. Benton R.E., Honig P.K., Zamani K. et al. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin. Pharmacol. Ther. 59:1996;383-388.
34. Fuhr U., Harder S., Lopez-Rojas P. et al. Increase of verapamil concentrations in steady state by coadministration of grapefruit juice. Naunyn-Schmeideberg's Arch. Pharmacol. 349:1994;R134.
35. Weber A., Jager R., Borner A. et al. Can grapefruit juice influence ethinylestradiol bioavailability? Contraception. 53:1996;41-47.
36. Kantola T., Kivisto K.T., Neuvonen P.J. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. 63:1998;397-402.
37. Bailey D.G., Arnold J.M.O., Munoz C. et al. Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin. Pharmacol. Ther. 53:1993;637-642.
38. Schmiedlin-Rebn P., Edwards D.J., Fitzsimmons M.E. et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab. Dispos. 25:1997;1228-1233.
39. Lown K.S., Bailey D.G., Fontana R.J. et al. Grapefruit juice increases felodipine oral bioavailability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 99:1997;2545-2553.
40. Lilja J.J., Kivisto K.T., Neuvonen P.J. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin. Pharmacol. Ther. 64:1998;477-483.
41. Schmassmann-Suhijar D., Bullingham R., Gasser R. et al. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet. 351:1998;1929-1930.
42. Lees R.S., Lees A.M. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N. Eng. J. Med. 333:1995;644-645.
43. Ahmad S. Diltiazem myopathy. Am. Heart J. 126(6):1993;1494-1495.
44. Corpier C.L., Jones P.H., Suki W.N. et al. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. J. Am. Med. Assoc. 260(2):1988;239-241.
45. Meier C., Stey C., Brack T. et al. Rhabdomyolysis in patients treated with simvastatin and cyclosporin: Role of the hepatic cytochrome P450 enzyme system activity. Schweiz Med Wochenschr. 125:1995;1342-1346. (in German).
46. Spach D.H., Bauwens J.E., Clark C.D., Burke W.G. Rhabdomyolysis associated with lovastatin and erythromycin use. West. J. Med. 154:1991;213-215.
47. Rodríquez JA, Crespo-Leiro MG, Paniagua MJ, et al. Rhabdomyolysis with HMC-CoA reductase inhibitors after heart transplant. Incidence and prognosis (abstract). Presented at XXth Congress of the European Society of Cardiology, August 1998, Vienna, Austria. Eur Heart J 1998;19(Suppl) (Abstract).
48. Keogh AM. Pravastatin confers superior survival after cardiac transplantation when compared to simvastatin (abstract). Presented at the American College of Cardiology Meeting, March 1999.
49. Bottorff M.B., Yenkowsky J.P., Cave D.G. Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy. Clin. Ther. 21(1):1999;218-235.
50. Gonzalez F.J., Nebert D.W. Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation. Trends Genet. 6(6):1990;182-186.
51. Berkow R, Fletcher AJ, Bondy PK, et al., editors. The Merck Manual of Diagnosis and Therapy, 15th ed. Rahway, NJ: Merck Sharpe and Dohme Research Laboratories, 1987.
52. Bertz R.J., Granneman G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32:1997;210-258.